Synonyms: Compound A [WO2021257532A1] | example 34 [US20210155606A1] | INCB-00928 | INCB00928
Compound class:
Synthetic organic
Comment: The chemical structure for zilurgisertib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a serine/threonine kinase inhibitor. It is one of the compounds that are claimed in Novartis' ALK2 (ACVR1) inhibitor patent US20210155606A1 [1], and it is also claimed in WO2021257532A1 by Incyte as "Compound A" [2]. Incyte have declared an ALK2 inhibitor (INCB00928) in their development pipeline. Name-to-structure was formally disclosed in early 2025 [3]. Zilurgisertib (INCB00928) is declared as an ATP-competitive, orally available and selective ALK2/ACVR1 inhibitor.
ALK2/ACVR1 is a serine/threonine protein kinase receptor for type I bone morphogenic protein (BMP), and this signalling pathway is crucial in bone formation, and hyperactivty of the pathway (e.g. by gain-of-function mutation ALK2R206H) is associated with diseases that are characterised by bone malformation, such as fibrodysplasia ossificans progressiva (FOP). ALK2 is also involved in the maintenance of iron homeostasis by governing production of the iron regulatory hormone hepcidin. Elevated hepcidin is thought to be a powerful driver of the pathophysiology of anemia that's associated with chronic disease. Inhibition of ALK2 upstream of hepcidin should increase circulating iron levels. Thus direct inhibition of ALK2/ACVR1 is a molecular mechanism that is being exploited for therapeutic potential in FOP and anemia arising from chronic kidney disease or myeloproliferative diseases. ![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1R,5S)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
12123 | zilurgisertib |
Synonyms ![]() |
Compound A [WO2021257532A1] | example 34 [US20210155606A1] | INCB-00928 | INCB00928 |
Database Links ![]() |
|
BindingDB Ligand | 451802 |
CAS Registry No. | 2173389-57-4 (source: WHO INN record) |
GtoPdb PubChem SID | 461663444 |
PubChem CID | 138628908 |
Search Google for chemical match using the InChIKey | KPRPFTOLWQQUAV-OCVAFRRMSA-N |
Search Google for chemicals with the same backbone | KPRPFTOLWQQUAV |
Search PubMed clinical trials | zilurgisertib |
Search PubMed titles | zilurgisertib |
Search PubMed titles/abstracts | zilurgisertib |
UniChem Compound Search for chemical match using the InChIKey | KPRPFTOLWQQUAV-OCVAFRRMSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | KPRPFTOLWQQUAV-OCVAFRRMSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Zilurgisertib (links to external site)
Cat. No. HY-145608 |